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Forced Expression of the Interferon Regulatory Factor 2 Oncoprotein Causes
Polyploidy and Cell Death in FDC-P1 Myeloid Hematopoietic
Progenitor Cells1
Rong-Lin Xie, Andre J. van Wijnen, Caroline M. van der Meijden, Janet L. Stein, and Gary S. Stein2
Department of Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts 01655
ABSTRACT
The IFN regulatory factor-2 (IRF-2) oncoprotein controls the cell cycle-
dependent expression of histone H4 genes during S phase and may func-
tion as a component of an E2F-independent mechanism to regulate cell
growth. To investigate the role of IRF-2 in control of cell proliferation, we
have constructed a stable FDC-P1 cell line (F2) in which expression of
IRF-2 is doxycycline (DOX)-inducible, and a control cell line (F0). Both
the F2 and F0 cell lines were synchronized in the G1 phase by isoleucine
deprivation, and IRF-2 was induced by DOX on release of cells from the
cell cycle block. Flow cytometric analyses indicated that forced expression
of IRF-2 has limited effects on cell cycle progression before the first
mitosis. However, continued cell growth in the presence of elevated IRF-2
levels results in polyploidy (>4n) or genomic disintegration (<2n) and cell
death. Western blot analyses revealed that the levels of the cell cycle
regulatory proteins cyclin B1 and the cyclin-dependent kinase (CDK)-
inhibitory protein p27 are selectively increased. These changes occur
concomitant with a significant elevation in the levels of the FAS-L protein,
which is the ligand of the FAS (Apo1/CD95) receptor. We also found a
subtle change in the ratio of the apoptosis-promoting Bax protein and the
antiapoptotic Bcl-2 protein. Hence, IRF-2 induces a cell death response
involving the Fas/FasL apoptotic pathway in FDC-P1 cells. Our data
suggest that the IRF-2 oncoprotein regulates a critical cell cycle check-
point that controls progression through G2 and mitosis in FDC-P1 hema-
topoietic progenitor cells.
INTRODUCTION
IRF-23 is a transcription factor with an important physiological role
in cell growth regulation and IFN responsiveness (1–4). Our labora-
tory initially identified IRF-2 [also known as Histone Nuclear
Factor-M (HiNF-M)]) as a transcription factor that interacts with a
phylogenetically conserved cell cycle regulatory element in the pro-
moter of a DNA replication-dependent human histone H4 gene (des-
ignated FO108, H4/n, or H4FN) that is up-regulated at the G1-S phase
transition in conjunction with DNA synthesis (5–13). IRF-2 is a
repressor of IRF-1-dependent gene activation (1–4, 14–16). How-
ever, other studies have revealed that the protein is a modest activator
of several genes, including histone H4 (5, 6), vascular cell adhesion
molecule-1 (VCAM-1) (17), and gp91phox (18). IRF-2 contains a
latent activation domain (19) and is a member of the winged helix-
turn-helix family of transcription factors (20, 21). The activity of
IRF-2 can be modulated by phosphorylation, acetylation, or interac-
tion with coregulatory factors (22–25). The protein regulates tran-
scription of its target genes at least in part by heterodimerization with
other IRFs, and by influencing the activity of large protein-DNA
complexes (enhanceosomes; Refs. 6, 26–29).
Many genes up-regulated in late G1 are involved in DNA synthesis
and nucleotide metabolism and are controlled, at least in part, by the
E2F class of transcription factors (30, 31). However, DNA replica-
tion-dependent histone genes represent an important exception to this
rule. The majority of histone genes are transcriptionally controlled at
the G1-S phase transition and lack functional E2F binding sites (32,
33). Our previous studies have shown that cell cycle-controlled his-
tone H4 genes represent physiological and S phase-specific target
genes for IRF factors (5, 6). Genetic ablation of IRF-2 abrogates the
cell cycle-dependent up-regulation of histone H4 gene expression
(10). One question that arises is whether the IRF-dependent regulation
of histone genes reflects broader participation of IRF factors in cell
cycle control. We propose that IRF factors may regulate cell prolif-
eration through transcriptional mechanisms that operate parallel to,
and/or independent of, E2F proteins.
Several studies have shown that IRF-2 has properties of an onco-
protein. For example, IRF-2 can influence cell proliferation both in
culture and in vivo and is capable of controlling cell cycle-regulatory
proteins as well as DNA-replication-dependent histone genes (5,
34–39). IRF-2 also plays a key role in cell growth and differentiation
of lymphocytes, and IRF-2 deficiency compromises development of
natural killer and T helper type 1 cells (40–42). We have previously
analyzed the regulation of IRF-2 and other histone gene transcription
factors during the cell cycle in FDC-P1 myeloid progenitor cells to
understand the role of IRF-2/HiNF-M in transcriptional control of
gene expression at the G1-S-phase transition (5, 43, 44). In this study,
we directly tested the role of IRF-2 in regulating cell cycle progres-
sion by conditionally expressing IRF-2 in stable FDC-P1 cell lines.
The principal result of our study is that forced expression of IRF-2
results in the abrogation of stringent cell growth control, reflected by
the formation of polyploid cells and cell death. Our findings suggest
that balanced physiological levels of IRF-2 are critical for normal cell
growth regulation.
MATERIALS AND METHODS
Construction of a DOX-inducible IRF-2 Expression Vector. We pre-
pared a conditional expression vector based on pRetroON (Clontech Labora-
tories, Inc., Palo Alto, CA) by cloning the full-length human IRF-2 coding
sequence into the BamHI restriction endonuclease site. The IRF-2 expression
vector was derived from pcDNA/IRF-2 (2, 5); this vector contains a 1.4-kbp
DNA fragment spanning the human IRF-2 coding sequence that was removed
by BamHI cleavage (New England Biolabs, Beverly, MA). The insert in the
pRetroON/IRF-2 construct was subject to automated DNA sequencing (ABI
model 377) to verify the start of the open reading frame and the orientation of
the cDNA insert.
Cell Culture and Stable Transfection Experiments. Actively proliferat-
ing cultures of FDC-P1 cells (45) were maintained in RPMI 1640 medium with
supplements (1% of IL-3-conditioned medium, 10% FCS, 100 units/ml peni-
cillin,100 g/ml streptomycin, and 0.2 M L-glutamine), at 37°C in humidified
air containing 5% CO2. RPMI 1640 and FCS were obtained from Life
Technologies, Inc. (Grand Island, NY). Penicillin, streptomycin, and L-gluta-
mine were purchased from Sigma Chemical Co. (St. Louis, MO). IL-3-
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conditioned medium was derived from WEHI-3B cells that produce and
secrete IL-3 (46). The optimal amount of IL-3 for cytokine-dependent growth
of FDC-P1 cells was empirically determined.
Experiments in which the DOX-inducible IRF-2 expression vector was
transiently introduced into FDC-P1 cells were performed using the calcium
phosphate-DNA precipitation method. Stable transfections with FDC-P1 cells
were performed with 0.5 to 1.0 g of pRetroON/IRF-2 expression construct or
empty vector containing the puromycin gene as a positive selectable marker.
Both plasmids were added into 0.15 ml of a 0.25 M CaCl2 solution in a 1.5-ml
sterile tube, and the solution was gently mixed. To this solution, we slowly
added 0.15 ml of 2 HEPES buffer (pH 7.11) and the CaCl2/DNA mixture
was allowed to precipitate for 10 to 15 min at room temperature. FDC-P1 cells
(2–3  106 cells) were collected by centrifugation (1500 rpm, IEC centrifuge)
in a 15-ml sterile tube (Corning Incorporated, Corning, NY). Cells were
resuspended in 2.7 ml of complete RPMI 1640 containing 15 mM -mercap-
toethanol. Cell suspensions were mixed with the calcium/DNA precipitate
followed by incubation for 5 min on ice, and then for 2 to 3 h at 37°C. The
transfected FDC-P1 cells were washed twice with 15 ml of 1 PBS. After
transfection, cells were allowed to recover for 16 h and 0.4 g/ml puromycin
was added to select for cells containing the pRetroON construct. Puromycin-
resistant colonies were pooled to obtain two polyclonal cell lines containing
either pRetroON/IRF-2 (F2 cells) or the parental pRetroON vector (F0 cells).
Cell Synchronization. F2 and F0 cells were synchronized by isoleucine
deprivation, which arrests cells in G1 phase. Actively growing cells (early-to-
mid-log phase) were precultured for 30 h in isoleucine-deficient RPMI 1640
(Life Technologies, Inc.) with supplements. At time zero, cells were released
from arrest by the addition of RPMI 1640 with supplements, with or without
25 ng/ml DOX (to induce IRF-2) for 72 h. Cells were harvested at selected
time points for S1 nuclease protection assays, Western blot analysis, and FACS
analysis.
S1 Nuclease Protection Assay. DNA oligonucleotides complementary to
the mouse homologue of the human FO108 H4 gene and the mRNA coding
sequence of the -actin gene (internal control) were used as probes to monitor
RNA levels as described previously (12). In brief, hybridization was performed
overnight with each of the -32P-oligonucleotide probes (10 fmoles) and 10 g
of RNA at 16°C in hybridization buffer [80% formamide, 100 mM sodium
citrate, 300 mM sodium acetate, 1 mM EDTA (pH 6.4)]. S1 nuclease digestions
were performed at 37°C for 40 min using 0.4 units of S1 nuclease per sample
in 200 l of S1 nuclease buffer [262.5 mM NaCl, freshly added 0.05 mg/ml
BSA, 1 mM ZnCl2, 37.5 mM sodium acetate (pH4.5)]. S1 protected DNA
fragments were electrophoretically separated for 2 h at 60W in a 6% denatur-
ing polyacrylamide gel (SequaGel), and signals were quantitated using the
STORM B40 Scanner.
Flow Cytometric Analysis. At the indicated time points, F2 and F0 cells
were harvested, washed with PBS, and fixed with 70% ethanol at 20°C for at
least 2 h. Cells were harvested by centrifugation and resuspended in a buffer
consisting of nine parts 0.05 M Na2HP04 and one part 25 mM citric acid containing
0.1% Triton X-100 (pH 7.8). Samples were incubated for 30 min at 25°C to extract
fragmented DNA (47). Cells were then washed with PBS and resuspended in 10
mM PIPES, 0.1 N NaCl, 2 mM MgCl2, and 0.1% Triton X-100, 20 g/ml
propidium iodide (Sigma Chemical Co.), and 50 g/ml RNase A (pH 6.8), and
incubated at room temperature for 30 min. The samples were analyzed for cell
cycle phase distribution or polyploidy and cell death by FACStar using the Consort
30 software (Becton Dickinson, Mountain View, CA).
Western Blot Analysis. Samples of F2 and F0 cells were harvested in
parallel with those used for FACS analysis and subjected to Western blot
analysis using the same methods that we described in detail previously (6).
Equal amounts of total cellular protein were subjected to 10 or 12% SDS-
PAGE. Proteins were transferred to polyvinylidene difluoride membranes
(Immobilon-P; Millipore Corp., Bedford, MA). Blots were incubated overnight
with primary antibodies using the indicated dilutions (-IRF-2 at 1:3000,
-p53 at 1:1500, -FAS-L at 1:1000, -Bax and -Bcl2 at 1:2000, -cyclin A
and -cyclin B1 at 1:1500, -CDK1 at 1:3000, -CDK2 at 1:5000, -p21 at
1:500–1000, -p27 at 1:3500, and -actin at 1:2500). Rabbit polyclonal
antibodies (Fas-L, Bax, Bcl-2, CDK2, and p27), mouse monoclonal antibodies
(p53, cyclin A, cyclin B1, and p21), and a goat polyclonal antibody (actin)
were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The
anti-IRF-2 polyclonal antibody was described previously (5). Blots were
further incubated with diluted (1:8,000–10,000) horseradish peroxidase-
conjugated secondary antibodies (Santa Cruz Biotechnology, Inc.). Immuno-
reactive protein bands were visualized by enhanced chemiluminescence de-
tection (ECL kit; Amersham Pharmacia Biotech Inc., Piscataway, NJ). Signal
intensities were quantitated by densitometry, and each experiment was re-
peated at least three times.
RESULTS
Elevation of IRF-2 Levels Up-Regulates Histone H4 Gene Ex-
pression at the G1-S-Phase Transition. To examine the role of
IRF-2 in regulating cell cycle progression, we prepared a stable
FDC-P1 cell line containing an integrated DOX-responsive IRF-2
vector that permits forced expression of IRF-2 on DOX administra-
tion. FDC-P1 cells exhibit normal cell cycle control of histone gene
transcription (43, 44); hence, the cell growth properties of FDC-P1
cells may approximate the phenotype of normal hematopoietic cells.
We determined that low (e.g., 1 pg/ml) and high (e.g., 100 ng/ml)
doses of DOX elevate IRF-2 levels to, respectively, 3- and 5-fold
above normal endogenous IRF-2 levels. We also established that the
IRF-2 construct mediates transcriptional activation of the histone H4
gene promoter in a DOX-dependent manner (data not shown).
We assessed the effect of elevating IRF-2 levels on endogenous
gene expression of a representative IRF-2-responsive target gene (i.e.,
the mouse homologue of the DNA replication-dependent histone H4/n
gene, also designated H4.1) that is normally induced at the G1-S-
phase transition (12). FDC-P1 cells were synchronized by isoleucine
deprivation (44, 48), and aliquots of cells were harvested at multiple
time points after release from the cell-cycle blockade. Samples were
analyzed by Western blot analysis to measure IRF-2 levels (Fig. 1, A
and B) and by S1 nuclease protection analysis to assess endogenous
H4 mRNA levels (Fig. 1, C and D). Western blot analysis shows that
F2 cells containing the IRF-2 expression vector have higher levels of
IRF-2 than F0 cells carrying the empty parental expression vector
(Fig. 1A, compare rows 1 and 2 with rows 3 and 4). Furthermore, F2
cells cultured in the presence of DOX (25 ng/ml) express higher levels
of IRF-2 than do F0 cells cultured in parallel under the same condi-
tions (Fig. 1A, compare rows 1 and row 3). However, apart from these
intended DOX-dependent differences in the levels of IRF-2, we note
that IRF-2 protein levels are also regulated during the cell cycle
irrespective of the presence of DOX (Fig. 1A, row 4), and that the
presence of DOX has a modest stimulatory effect on endogenous
IRF-2 levels (Fig. 1A, row 3). Thus, there are at least three factors that
contribute to the steady-state levels of IRF-2 in synchronized FDC-P1
cells: presence of IRF-2 expression vector; cell cycle stage; and
presence of DOX. However, quantitation of the Western blot signals
(Fig. 1B) reveals that IRF-2 levels are consistently higher in F2 cells
cultured in the presence of DOX than F2 cells cultured without DOX,
or F0 cells that lack the IRF-2 expression construct. The DOX-
dependent elevation of IRF-2 levels in F2 cells results in a significant
increase in expression of the histone H4/n gene based on S1 nuclease
protection analysis, and this effect on H4/n gene expression is not
apparent in F2 cells cultured without DOX or in F0 cells (Fig. 1, C and
D). We conclude that DOX elevates IRF-2 expression in F2 cells
above physiological levels, with a functional effect on the expression
of a cell cycle-controlled and IRF-2-responsive target gene.
Normal Cell Cycle Progression beyond the G1-S Phase Transi-
tion in FDC-P1 Cells Expressing Supraphysiological Levels of
IRF-2. We analyzed whether elevation of IRF-2 levels during G1 and
the subsequent S phase affects cell cycle progression by evaluating the
cell cycle distribution of FDC-P1 cells using FACS analysis (Fig. 2A).
The F2 and F0 cell lines were synchronized by isoleucine deprivation and
cultured in the presence or absence of DOX. The results show that the
proportion of cells in S phase is very similar in F0 cells independent of
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the presence of DOX and in F2 cells grown in the absence of DOX at all
of the time points examined between 4 and 16 h after cell cycle entry
(Fig. 2B). The proportion of F2 cells in S phase seems to be modestly
reduced in the presence of DOX (i.e.,10% decrease) relative to F2 cells
grown without DOX or to F0 cells (Fig. 2B). We conclude that a small
subset of IRF2-expressing cells may have lost the ability to enter S phase,
perhaps because of a specific cell cycle block. However, the majority of
F2 cells that express IRF2 at elevated levels retain the ability to progress
unimpeded beyond the first G1-S-phase transition.
Deregulated Expression of IRF-2 Causes Polyploidy and Cell
Death in FDC-P1 Hematopoietic Progenitor Cells. We next as-
sessed whether sustained elevation of IRF-2 in FDC-P1 cells influ-
ences cell growth-regulatory parameters and the cellular morphology
of FDC-P1 cells (Figs. 3 and 4). The cell cycle distribution of F2 and
F0 cells was analyzed by FACS in the presence or absence of DOX
(Fig. 3). We validated that IRF-2 levels are only increased in F2 cells
cultured in the presence of DOX and are not changed in F0 cells
irrespective of the presence of DOX (Fig. 3A). For comparison, CDK2
levels were not altered in either F2 or F0 cells (Fig. 3A). The results
from FACS analysis reveal that continuous up-regulation of IRF-2
above normal endogenous levels for 2–3 days causes an increase in
polyploid cells (4n or 8n; Fig. 3B, bottom row, right panel). Increased
polyploidy occurs concomitantly with a decrease in the percentage of
cells in S phase and an increase of cells in G2-M (Fig. 3C). Apart from
polyploidy (Fig. 3D), we also observed a significant fraction of cells
with a genome content of less than 2n (Fig. 3, B, bottom row, right
panel, and E). Microscopic examination of F2 cells cultured in the
presence of DOX reveals many cells that are larger than normal (Fig.
4, right bottom panel), consistent with an increase in polyploid cells
and/or cells in G2-M phase. In addition, cell death is evident from an
increase in small and partially fragmented cells in the same prepara-
tion (Fig. 4, right bottom panel). Taken together, our results indicate
that deregulation of the level of IRF-2 alters the cell growth properties
of FDC-P1 cells and results in polyploidy and cell death.
Forced Expression of IRF-2 in FDC-P1 Cells Elevates FAS-L,
the Activating Component of the Fas/FasL Apoptotic Pathway.
To understand the mechanism by which IRF-2 causes polyploidy and
cell death in FDC-P1 cells, we performed Western blot analyses using
Fig. 1. Forced expression of IRF-2 up-regulates
histone H4 gene expression at the G1-S-phase tran-
sition. A, Western blot analysis with an IRF-2 an-
tibody using lysates from F2 and F0 cells at differ-
ent times after release from synchronization in G1
phase by isoleucine deprivation. IRF-2 expression
was induced by DOX addition at 0 h (see Fig. 2B)
, induced with 25 ng/ml DOX;, noninduced. B,
quantitation of the Western blot data presented in
A. C, S1 nuclease protection assay of RNA samples
isolated at different times during cell cycle progres-
sion using radio-labeled oligonucleotides (H4
probe and Actin probe) detecting histone H4 and
actin mRNAs. , the main S1 nuclease protected
products for each probe, and either the mouse H4.1
gene or the -actin gene as described previously
(12). D, graph showing the levels of histone H4
mRNA normalized relative to -actin mRNA in F0
and F2 cells in the absence () or presence () of
DOX; quantitation of the S1 nuclease data from C
was performed using a STORM B40 scanner.
Fig. 2. Retention of competency for cell cycle progres-
sion through the first S-phase transition after forced expres-
sion of IRF-2. A, flow-cytometric analysis of F2 and F0 cell
lines cultured in the presence () or absence () of DOX
and analyzed at different times after release from isoleucine
block The graphs show the number of cells (vertical axis)
with different DNA contents (horizontal axis) as measured
by propidium iodide (PI). B, graph showing the percentage
of F2 and F0 cells in S phase (vertical) in the presence or
absence of DOX at different times (horizontal) during cell
cycle traverse.
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antibodies against cell cycle regulatory proteins (i.e., cyclins A and
B1, CDK1, and CDK2, as well as the CDK inhibitors p27 and p21)
and apoptosis-related factors (p53, FAS-L, Bax and Bcl-2; Fig. 5). As
expected, DOX increased IRF-2 levels in F2 cells (Fig. 5A). We find
that the levels of the cell cycle-regulatory proteins cyclin B1 and the
CDK-inhibitory protein p27 are selectively increased after DOX en-
hancement of IRF-2 levels (Fig. 5B). However, in the same cells, there
are no appreciable differences in the levels of CDK1 (CDC2), CDK2,
and cyclin A, whereas the CDK-inhibitory protein p21 is not detected
(Fig. 5B). The selective increase in the levels of cyclin B1 and p27
indicate that forced expression of IRF-2 arrests cells in G2-M. These
Fig. 5. Modulations in the level of cell cycle- and apoptosis-related factors by
IRF-2 induction in FDC-P1 cells. F2 cells were cultured in complete RPMI 1640 plus
IL-3-conditioned medium in the absence () or presence () of 25 ng/ml DOX.
Whole-cell lysates, isolated at 1, 2, or 3 days after plating, were analyzed by Western
blot with the indicated antibodies. No signal was observed for p21 (empty strip),
whereas p27 levels were readily detectable; -actin was used as control for equal
protein loading.
Fig. 3. Apoptosis and polyploidy of FDC-P1 cells during
prolonged forced expression of IRF-2. F0 and F2 cells were
synchronized and then cultured in conditioned medium (see
“Materials and Methods”) in the absence () or presence ()
of DOX for several days. A, Western blots showing a compar-
ison of IRF-2 levels in F2 and F0 cells at the indicated days of
treatment. CDK2 levels were monitored as internal control;
forced IRF-2 expression does not cause a change in CDK2
protein levels. B, flow-cytometric assays reveal an increased
proportion of cells exhibiting apoptosis or polyploidy only in
F2 cells in which IRF-2 levels are elevated by DOX induction,
but not in noninduced F2 cells or F0 cells under inducing or
noninducing conditions. C, graph showing the percentage of
cells in the G1, S phase, or G2-M at day 3 after DOX admin-
istration in F0 and F2 cells. The percentage of F0 (squares) and
F2 (circles) cells exhibiting polyploidy (D) or undergoing ap-
optosis (E) at different days in culture in the presence (open
symbols) or absence (closed symbols) of DOX. The graphs are
based on results from at least three independent flow-cytomet-
ric assays.
Fig. 4. IRF-2-dependent alterations in cellular morphology of FDC-P1 cells. Cell death
and polyploid morphology in IRF-2-overexpressing F2 cells. The F0 and F2 cells were
cultured in the absence () or presence () of 25 ng/ml DOX for 3 days. Photographs
were taken using a phase-contrast microscope with a 100 objective. Cell remnants
attributable apoptosis (arrowheads) and polyploid cells (arrows) are indicated. Alterations
in cellular morphology were observed only in F2 cells in which IRF-2 levels were
elevated, and not in noninduced F2 cells nor in induced and noninduced F0 cells.
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results suggest that IRF-2 alters a mitosis-related checkpoint that may
be mechanistically linked to the increase in polyploidy.
We observe that increased IRF-2 expression causes a striking
elevation in the levels of the FAS-L protein that activates the FAS
(Apo1/CD95) pathway (Fig. 5C). There is also a change in the ratio of
the levels for the antiapoptotic Bcl-2 protein (modest decrease) and
the apoptosis-promoting Bax protein (no major difference; Fig. 5C).
For comparison, the levels of the tumor suppressor protein p53 remain
similar in the absence or presence of DOX (Fig. 5C). Thus, the data
of Fig. 5 and those presented in Fig. 4 indicate that IRF-2-induced cell
death occurs concomitantly with elevation of a component of the
Fas/FasL apoptotic pathway in FDC-P1 cells.
DISCUSSION
In this study, we characterized the IRF-2 oncoprotein as a compo-
nent of an E2F-independent mechanism that controls cell prolifera-
tion. Our results indicate that deregulated expression of IRF-2 alters
cell growth control of hematopoietic progenitor cells. We found that
forced expression of IRF-2 does not affect progression through the G1
and S phase stages of the cell cycle but alters cell growth by increas-
ing the proportion of G2-M cells, as well as by causing polyploidy and
cell death. Cells that express IRF-2 above physiological levels exhibit
increased expression of cyclin B1 and the CDK-inhibitory protein
p27. Because cyclin B1 activates the mitotic CDK1(CDC2), and the
p27 protein is capable of inhibiting CDK1 activity, these data indicate
that cells become arrested in G2-M. Forced expression of IRF-2 also
increases the number of tetraploid cells, which implies a defect in
chromosomal segregation. A subset of these cells exhibit a DNA
content 4n, which indicates that cells retain competency to initiate
a second round of DNA synthesis. Taken together, our findings
suggest that forced expression of IRF-2 compromises a mitotic check-
point (49), thereby creating a cell cycle defect that causes polyploidy
and cell death.
Polyploidization is observed during megakaryocytic differentiation,
but does not normally occur in other hematopoietic cells (50). The
formation of polyploid FDCP-1 cells by forced elevation of IRF-2
levels is related to failure to undergo normal mitosis. The resulting
tetraploidy may activate a p53-dependent cell cycle checkpoint in G1
(51), and this could trigger apoptosis. However, because tetraploid
IRF-2-overexpressing cells can reduplicate their genome to form
polyploid (4n) cells, these cells do not appear to arrest in G1. Apart
from p53 (52), several other transcription factors including c-Myc
(53), p120E4F (54), and Trident (54) are involved in the formation of
polyploid cells. For example, overexpression of the c-myc oncopro-
tein causes polyploidy in fibroblasts and apoptosis, and then proceeds
in normal primary but not immortalized fibroblasts (53). Hence,
c-myc and IRF-2 may share the ability to generate genomic instability
when their expression is deregulated.
Hematopoietic stem cells represent uncommitted and undifferenti-
ated blood cell precursors that respond to environmental signals by
proliferative expansion and subsequent differentiation into mature
cells. FDC-P1 cells are mouse myeloid progenitor cells that strictly
depend on IL-3 for their survival. Absence of cytokines can trigger
cell death in FDC-P1 cells, although there are FDC-P1 sublines that
are at least partially resistant to apoptosis (55, 56). The IRF-2-
dependent up-regulation of the CDK-inhibitory protein p27 in
FDC-P1 cells, which occurs in parallel with increased apoptosis,
could cause growth factor desensitization by interfering with the
activities of CDKs (e.g., D-type cyclins and CDK4/6) that integrate
growth factor-dependent signaling pathways during G1. However,
results from our cell synchronization studies with FDC-P1 cells that
are blocked in G1 reveals that competency for cell cycle progression
through G1 and S phase occurs irrespective of elevations in IRF-2
levels. Therefore, we favor the interpretation that elevation of IRF-2
does not directly affect cytokine-dependent signaling in FDC-P1 cells.
IRF-2 may have a specific role in cell death by apoptosis. For
example, IRF-2 is up-regulated during the apoptotic stage of osteo-
blast differentiation that occurs as a normal component of the main-
tenance of bone tissue organization (57). In FDC-P1 hematopoietic
progenitor cells, IRF-2 may directly trigger apoptosis by regulating
components of the Fas (APO-1/CD95) apoptotic pathway. Fas (APO-
1/CD95) is a cell surface receptor that can mediate apoptosis and is
related to the tumor necrosis factor receptor family. Cells can undergo
apoptosis on expression and binding of the FasL to the Fas receptor.
It has previously been shown that FasL expression in T cells is
transcriptionally regulated by IRF transcription factors, and that IRF-1
and IRF-2 are each capable of interacting with the FAS-L promoter
and activating FasL expression (58). Consistent with these findings,
our data show that IRF-2 expression triggers a dramatic up-regulation
of FasL in FDC-P1 cells, and this may activate the Fas/FasL apoptotic
pathway. The product of the proto-oncogene Bcl-2, a membrane-
associated protein, may interfere with Fas-dependent apoptosis (55,
56), and we found that overexpression of IRF-2 in FDC-P1 cells
results in down-regulation of Bcl-2. Taken together, one model that
can account for our findings is that the emergence of polyploidy,
together with IRF-2 mediated changes in FasL levels and the con-
comitant activation of the FAS apoptotic pathway, may be responsible
for cell death.
IRF-2 is normally up-regulated by IRF-1 in direct response to the
antiproliferative actions of IFNs. Initial studies suggested that the
main function of IRF-2 is to attenuate IRF-1 dependent gene activa-
tion (reviewed in Ref. 3). Our study indicates that conditional up-
regulation of IRF-2 induces cell death by enhancing the endogenous
levels of FasL. Hence, one important physiological function of IRF-2
is that it may extend the antiproliferative signal of IFNs by promoting
conditions conducive of apoptosis. In summary, we have shown here
that unbalanced expression of IRF-2 influences proliferative expan-
sion of FDC-P1 hematopoietic progenitor cells by causing polyploidy
and inducing apoptosis. Thus, our data provide important new evi-
dence for the cell growth regulatory properties of IRF-2.
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